| Protocol | Description | Details |
| 0S-08-9 | Short-Term Starvation Prior to Standard Chemotherapy with Gemcitabine and Cisplatin: Feasibility and Impact on Toxicity.
Click on protocol number to see eligibility requirements
Protocol Treatment Modalities:
| Randomized: No
Principal Investigator(s):
Tanya Dorff
Staff Members:
Charlean Ketchens
Francisco Acosta
Lagrimas Ilagan
|
| 0S-09-4 | A Randomized Controlled Trial of Enoxaparin Thromboprophylaxis in Cancer Patients with Elevated Tissue Factor Bearing Microparticles.
Click on protocol number to see eligibility requirements
Protocol Treatment Modalities:
Other
| Randomized: Yes
Principal Investigator(s):
Howard Liebman
Staff Members:
Laurie Hornor
Melissa Peralta
|
| 18M-07-1 | Phase II Study of AZD2171 (NSC#732208) in Patients with Malignant Mesothelioma.
Click on protocol number to see eligibility requirements
Protocol Treatment Modalities:
Anti-Angiogenesis
| Randomized: No
Principal Investigator(s):
Barbara Gitlitz
Staff Members:
Charlean Ketchens
Eduardo Mejia
Gina Tse
Lagrimas Ilagan
|
| 2N-06-7 | A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of Single-Agent Tarceva (Erlotinib) Following Complete Tumor Resection with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non-Small Cell Lung Carcinoma who have EGFR-Positive Tumors.
Click on protocol number to see eligibility requirements
Protocol Treatment Modalities:
Biological Response Modifier
| Randomized: Yes
Principal Investigator(s):
Barbara Gitlitz
Staff Members:
Charlean Ketchens
Gina Tse
Lagrimas Ilagan
Vatche Stepanian
|
| 2N-06-8 | A Multi-Center, Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Cancer Vaccine Stimuvax (L-BLP25 or BLP25 Liposome Vaccine) in Non-Small Cell Lung Cancer (NSCLC) Subjects with Unresectable Stage III Disease.
Click on protocol number to see eligibility requirements
Protocol Treatment Modalities:
Vaccine
| Randomized: Yes
Principal Investigator(s):
Barbara Gitlitz
Staff Members:
Charlean Ketchens
Gina Tse
Lagrimas Ilagan
Vatche Stepanian
|
| 2N-08-1 | A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II Study of the Efficacy and Safety of Apricoxib in Combination with Erlotinib in Non-Small Cell Lung Cancer Patients.
Click on protocol number to see eligibility requirements
Protocol Treatment Modalities:
Biological Response Modifier
Chemotherapy: Systemic
| Randomized: Yes
Principal Investigator(s):
Barbara Gitlitz
Staff Members:
Charlean Ketchens
Eduardo Mejia
Gina Tse
Lagrimas Ilagan
|
| 2N-08-6 | Development of DNA Methylation Markers for Early Detection of Lung Cancer.
Click on protocol number to see eligibility requirements
Protocol Treatment Modalities:
| Randomized: No
Principal Investigator(s):
Ite Laird
Staff Members:
Charlean Ketchens
Eduardo Mejia
Gina Tse
Lagrimas Ilagan
|
| 2O-08-3 | A Phase IB/II Trial of AMG 479 or AMG 102 in Combination with Platinum-Based Chemotherapy as First-Line Treatment for Extensive Stage Small Cell Lung Cancer.
Click on protocol number to see eligibility requirements
Protocol Treatment Modalities:
Chemotherapy: Systemic
Immunotherapy
| Randomized: No
Principal Investigator(s):
Barbara Gitlitz
Staff Members:
Eduardo Mejia
Gina Tse
Lagrimas Ilagan
Xiomara Menendez
|
| ctsu/E1505 | A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (=/>4 cm) - IIIA Non-Small Cell Lung Cancer (NSCLC).
Click on protocol number to see eligibility requirements
Protocol Treatment Modalities:
Anti-Angiogenesis
Chemotherapy: Systemic
| Randomized: Yes
Principal Investigator(s):
Barbara Gitlitz
Staff Members:
Charlean Ketchens
Gina Tse
Lagrimas Ilagan
Lynette Sebastian
|
| RTOG-0517 | Randomized Phase III Trial to Evaluate RadioPharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases from Lung, Breast, and Prostate Cancer.
Click on protocol number to see eligibility requirements
Protocol Treatment Modalities:
Other
| Randomized: Yes
Principal Investigator(s):
Parvesh Kumar
Staff Members:
Carryl Du Bois
|
| SWOG-S0533 | A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Addition of Bevacizumab (NSC-704865) in Three Cohorts of Patients with Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer.
Click on protocol number to see eligibility requirements
Protocol Treatment Modalities:
Anti-Angiogenesis
Chemotherapy: Systemic
Radiation: External
| Randomized: No
Principal Investigator(s):
Barbara Gitlitz
Staff Members:
Charlean Ketchens
Eduardo Mejia
Gina Tse
Lagrimas Ilagan
|
| SWOG-S0720 | Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients with Stage I Non-Small Cell Lung Cancer (NSCLC).
Click on protocol number to see eligibility requirements
Protocol Treatment Modalities:
Chemotherapy: Systemic
| Randomized: No
Principal Investigator(s):
Barbara Gitlitz
Staff Members:
Charlean Ketchens
Eduardo Mejia
Gina Tse
Lagrimas Ilagan
|
| SWOG-S9925 | Lung Cancer Specimen Repository Protocol, Ancillary.
Click on protocol number to see eligibility requirements
Protocol Treatment Modalities:
| Randomized: No
Principal Investigator(s):
Barbara Gitlitz
Staff Members:
Charlean Ketchens
Gina Tse
Lagrimas Ilagan
Vatche Stepanian
|
| TEST002 | Test protoc ol 002 this jkjrejketkerkthres sdf sdf
Click on protocol number to see eligibility requirements
Protocol Treatment Modalities:
Autologous Bone Marrow Transplant
Biological Response Modifier
Chemotherapy: Local
Genetic
| Randomized: Not Asked
Principal Investigator(s):
Lenny Africano
Lilia Frausto
Noemi Adalin
Staff Members:
Noemi Adalin
|
